Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2020, specifically dated February 5, 2020. The document serves as a transaction notification regarding share allocations for Non-Executive Directors under the company's share allocation arrangements for the service period of October 1, 2019, to December 31, 2019.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific equity transactions involving Persons Discharging Managerial Responsibilities (PDMRs).
| Director Name | Position | Instrument | Volume | Price |
|---|---|---|---|---|
| Sir Jonathan Symonds | Non-Executive Chairman | Ordinary Shares | 2,430.556 | £18.00 |
| Mr Vindi Banga | Senior Independent Non-Executive Director | Ordinary Shares | 399.306 | £18.00 |
| Dr Vivienne Cox | Independent Non-Executive Director | Ordinary Shares | 295.139 | £18.00 |
| Ms Lynn Elsenhans | Independent Non-Executive Director | ADSs | 1,055.371 | $46.88 |
| Dr Laurie Glimcher | Independent Non-Executive Director | ADSs | 1,172.635 | $46.88 |
| Dr Jesse Goodman | Independent Non-Executive Director | ADSs | 353.812 | $46.88 |
| Ms Judy Lewent | Independent Non-Executive Director | ADSs | 394.248 | $46.88 |
| Mr Urs Rohner | Independent Non-Executive Director | Ordinary Shares | 399.306 | £18.00 |
Material Changes
The filing reports the acquisition of notional shares and ADSs by seven Non-Executive Directors. These transactions represent compensation for services rendered in the fourth quarter of 2019. There are no material changes to the company's financial position or operations reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. It is a regulatory disclosure of director shareholdings.
Key Facts for Investor Verification
- Verify the total number of Ordinary Shares and ADSs allocated to Non-Executive Directors for the Q4 2019 service period.
- Confirm the transaction price of £18.00 per Ordinary Share and $46.88 per ADS used for these allocations.
- Note that these are "notional" acquisitions under share allocation arrangements, distinct from open market purchases.
- Recognize that this filing contains no operational or financial performance data for GSK.